Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11322346PMC
http://dx.doi.org/10.3389/fchem.2024.1467074DOI Listing

Publication Analysis

Top Keywords

editorial hot
4
hot topic
4
topic excited
4
excited state
4
state processes
4
processes biomolecules
4
editorial
1
topic
1
excited
1
state
1

Similar Publications

TLR7/8/9 agonists and low-dose cisplatin synergistically promotes tertiary lymphatic structure formation and antitumor immunity.

NPJ Vaccines

January 2025

Key Laboratory of Medical Molecular Virology, School of Basic Medical Sciences, Fudan University, Shanghai, 200032, China.

In situ vaccination (ISV) triggers antitumor immune responses using the patient's own cancer antigens, yet limited neoantigen release hampers its efficacy. Our novel combination therapy involves low-dose local cisplatin followed by ISV with a TLR7/8/9 agonist formulation (CR108), in which CR108 boosts and sustains the antitumor responses induced by the cisplatin-released neoantigens. In mouse models, the cisplatin+CR108 combination significantly outperformed cisplatin or CR108 alone in abrogating established 4T1 and B16 tumors.

View Article and Find Full Text PDF

Background/aims: We investigated the clinical practice patterns of Korean endoscopists for the endoscopic resection of colorectal polyps.

Methods: From September to November 2021, an online survey was conducted regarding the preferred resection methods for colorectal polyps, and responses were compared with the international guidelines.

Results: Among 246 respondents, those with <4 years, 4-9 years, and ≥10 years of experience in colonoscopy practices accounted for 25.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!